Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC)

References

• Agrawal N, Frederick MJ, Pickering CR, et al. (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 6046:1154–7
   Google Scholar
• Araújo A, Ribeiro R, Azevedo I, et al. (2007). Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer. Oncologist 2:201–10
   Google Scholar
• Basu R, Mandal S, Ghosh A, Poddar TK. (2008). Role of tobacco in the development of head and neck squamous cell carcinoma in an eastern Indian population. Asian Pac J Cancer Prev 9:381–6
   PubMedGoogle Scholar
• Chiu TJ, Chen YJ, Rau KM, et al. (2013). Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma. Biomarkers 18:687–98
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, et al. (2006). Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170–6
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. (2003). Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348–54
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, et al. (2003). Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–7
   PubMed Web of Science ®Google Scholar
• Cortesina G, Martone T. (2006). Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature. Acta Otorhinolaryngol Ital 26:317–25
   PubMedGoogle Scholar
• Denaro N, Lo Nigro C, Natoli G, et al. (2011). The role of p53 and MDM2 in head and neck cancer. ISRN Otolaryngology 2011:article ID 931813, 8 pages
   Google Scholar
• Dibb NJ, Dilworth SM, Mol CD. (2004). Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev 4:718–27
   Google Scholar
• Elahi M, Rakhshan V, Ghasemian NT, Moshref M. (2012). Prognostic value of transforming growth factor beta 1 [TGF-β1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers 17:21–7
   PubMed Web of Science ®Google Scholar
• Farnebo L, Jedlinski A, Ansell A, et al. (2009). Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med 4:549–56
   Google Scholar
• Greulich H, Chen TH, Feng W, et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:313
   PubMed Web of Science ®Google Scholar
• Hama T, Yuza Y, Saito Y, et al. (2009). Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14:900–8
   PubMed Web of Science ®Google Scholar
• Hang L, Yunjian P, Yuan L, et al. (2013). Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 79:8–13
   PubMedGoogle Scholar
• Harari PM, Allen GW, Bonner JA. (2007). Biology of interactions: anti epidermal growth factor receptor agents. J Clin Oncol 25:4057–65
   PubMed Web of Science ®Google Scholar
• Hsieh YY, Tzeng CH, Chen MH, et al. (2012). Epidermal growth factor receptor R521K polymorphism shows favorable outcome to cetuximab-based treatment in KRAS wild-type colorectal cancer patients. Cancer Sci 4:791–6
   Google Scholar
• Jorissen RN, Walker F, Pouliot N, et al. (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284:31–53
   PubMed Web of Science ®Google Scholar
• Kaneko K, Kumekawa Y, Makino R, et al. (2010). EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 15:65–72
   Web of Science ®Google Scholar
• Krohn V, Wiegand S, Werner JA, Mandic R. (2011). EGFR codon 497 polymorphism – implications for receptor sensitivity to inhibitors in HNSCC cell lines. Anticancer Res 1:59–65
   Google Scholar
• Lee JW, Soung YH, Kim SY, et al. (2005). Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11:2879–82
   PubMed Web of Science ®Google Scholar
• Lemos-Gonzalez Y, Paez de la Cadena M, Rodriguez-Berrocal FJ, et al. (2007). Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biol 28:273–9
   PubMedGoogle Scholar
• Linardou H, Dahabreh IJ, Bafaloukos D, et al. (2009). Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Rev Clin Oncol 6:352–66
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Hung MC. (2006). EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 3:211–18
   Google Scholar
• Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al. (2006). Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carinoma. Eur J Cancer 42:109–11
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–39
   PubMed Web of Science ®Google Scholar
• Mellon K, Wright C, Kelly P, et al. (1995). Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 2:919–25
   Google Scholar
• Miller SA, Dykes DD, Polesky HF. (1988). A simple salting-out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 16:1215
   PubMed Web of Science ®Google Scholar
• Na II, Kan HJ, Cho SY, et al. (2007). EGFR mutations and human papillomavirus is squamous cell carcinoma of tongue and tonsil. Eur J Cancer 43:520–6
   PubMed Web of Science ®Google Scholar
• Nagalakshmi K, Jamil K, Usharani P. (2013). Association of EGFR gene polymorphisms in head and neck cancer patients with tobacco and alcohol consuming habits. Biol Med 5:69–77
   Google Scholar
• Nomura M, Shigematsu H, Li L, et al. (2007). Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4:125
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinicalresponse to gefitinib therapy. Science 304:1497–500
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–11
   PubMed Web of Science ®Google Scholar
• Rong R, Tull J, Zhang S. (2012). Molecular biomarker profile of EGFR copy number, KRAS and BRAF mutations in colorectal carcinoma. J Solid Tumors 2:27–31
   Google Scholar
• Sabitha K, Kaiser J. (2006). Analysis of EGFR gene mutations which have a response to quinazolin inhibitors. Comparative Evol Genom Proteom 5:229–32
   Google Scholar
• Sabitha K, Reddy MVV, Kaiser J. (2008). GST genotypes in head and neck cancer patients and its clinical implications. Afr J Biotechnol 7:3853–9
   Google Scholar
• Sabitha K, Reddy MVV, Kaiser J. (2010). Smoking related risk involved in individuals carrying genetic variants of CYP1A1 gene in head and neck cancer. Cancer Epidemiol 34:5587–92
   Google Scholar
• Sahoo R, Harini VV, Babu VC, et al. (2011). Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73:316–19
   PubMedGoogle Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–81
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–46
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163–7
   PubMed Web of Science ®Google Scholar
• Stransky N, Egloff AM, Tward AD, et al. (2011). The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157–60
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Sakamoto H, et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829–37
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmén M, Junttila TT, et al. (2005). Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2:273–8
   Google Scholar
• Temam S, Kawaguchi H, El-Naggar AK, et al. (2007). Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164–70
   PubMed Web of Science ®Google Scholar
• Tokumo M, Toyooka S, Kiura K, et al. (2005). The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167–73
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Layfield LJ. (2006). Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Modern Pathol 19:634–40
   PubMed Web of Science ®Google Scholar
• Wu JY, Wu SG, Yang CH, et al. (2008). Lung cancer with EGFR exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14:4877–82
   PubMed Web of Science ®Google Scholar
• Yen C-Y, Huang C-Y, Hou M-F, et al. (2013). Evaluating the performance of fibronectin 1 (FN1), integrin α4β1 (ITGA4), syndecan-2 (SDC2), and glycoprotein CD44 as the potential biomarkers of oral squamous cell carcinoma (OSCC). Biomarkers 18:63–72
   PubMed Web of Science ®Google Scholar
• Yoshikawa S, Kukimoto-Niino M, Parker L, et al. (2013). Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene 32:27–38
   PubMed Web of Science ®Google Scholar